Sandbox Reserved 384: Difference between revisions
No edit summary |
No edit summary |
||
| Line 16: | Line 16: | ||
===Ongoing Research=== | ===Ongoing Research=== | ||
The significance of this receptor makes it a prime target for diabetes research. Incretins are a class of biological molecules that act like gastrointestinal hormones. One such example is Glucagon-like peptide-1 (GLP-1) which works with GIP to regulate the body's insulin levels. Synthetic versions of this peptide hormone have been made to treat people with type-2 diabetes. It works by stimulating GIP production as well as insulin secretion causing the body to properly regulate its blood glucose levels like someone without diabetes. | The significance of this receptor makes it a prime target for diabetes research. Incretins are a class of biological molecules that act like gastrointestinal hormones. One such example is Glucagon-like peptide-1 (GLP-1) which works with GIP to regulate the body's insulin levels. Synthetic versions of this peptide hormone have been made to treat people with type-2 diabetes. It works by stimulating GIP production as well as insulin secretion causing the body to properly regulate its blood glucose levels like someone without diabetes. The benefit of synthetic GLP-1 is that it is not protein and so would not be degraded as easily therefore prolonging the benefits of the drug. One such example is Byetta<ref>"Byetta." BYETTA (exenatide) Injection | Welcome to BYETTA.com. Amylin Pharmaceuticals, Inc., 2011. Web. 02 Dec. 2011. <http://www.byetta.com/Pages/index.aspx></ref>. | ||
[[Image:F3.large.jpg |400px| |left| |caption=<ref>"A Novel Pathway for Regulation of Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor Expression in ß Cells." The FASEB Journal 17.1 (2003): 91-93. Print.</ref>|]] | [[Image:F3.large.jpg |400px| |left| |caption=<ref>"A Novel Pathway for Regulation of Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor Expression in ß Cells." The FASEB Journal 17.1 (2003): 91-93. Print.</ref>|]] | ||